<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04830462</url>
  </required_header>
  <id_info>
    <org_study_id>H-20028894 or 126496</org_study_id>
    <nct_id>NCT04830462</nct_id>
  </id_info>
  <brief_title>Impact of LTBI Treatment on Glucose Tolerance and Chronic Inflammation</brief_title>
  <official_title>Impact of LTBI Treatment on Glucose Tolerance and Chronic Inflammation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Herlev and Gentofte Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Herlev and Gentofte Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be investigating the effect of latent tuberculosis infection (LTBI) treatment&#xD;
      on glucose tolerance and low-grade inflammation. Almost a century ago, researchers proposed&#xD;
      that diabetes (DM) was associated with increased risk of Tuberculosis infection (TB). A more&#xD;
      recent systematic review concluded that DM increases the relative risk for TB 3.1 times.&#xD;
      Reversely, TB may affect the glycaemic control; TB is in many cases a chronic infection&#xD;
      characterised by long term low-grade inflammation and weight loss, and persons with TB are&#xD;
      known to be at risk of hyperglycaemia and DM at time of diagnosis. A latent infection with&#xD;
      the m.tuberculosis bacteria is &quot;silent&quot; without symptoms.&#xD;
&#xD;
      1,7 billion have LTBI on a global scale. Event though the infected person does not experience&#xD;
      symptoms, increased background inflammation has been shown in LTBI patients in previous&#xD;
      studies. We also know that an increase in inflammatory markers precedes clinical development&#xD;
      of DM, and that subclinical inflammation contributes to insulin resistance. We hypothesise&#xD;
      that LTBI contributes to dysregulated glucose metabolism due to increased low-grade&#xD;
      inflammation, and that treatment will reduce low-grade inflammation and improve glucose&#xD;
      tolerance.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 15, 2021</start_date>
  <completion_date type="Anticipated">May 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 15, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The study consists of two arms with different patient populations. Both arms will receive identical treatment. Arm A will have type 2 diabetes and latent tuberculosis infection (LTBI). Group B will not have any form of diabetes, but LTBI.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>OGTT (oral glucose tolerance test)</measure>
    <time_frame>Time Frame: 4-6 months (depending on treatment)</time_frame>
    <description>Reduction in plasma glucose area under the curve during OGTT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in insulin production</measure>
    <time_frame>Time Frame: 4-6 months (depending on treatment)</time_frame>
    <description>Insulin/c-peptid, HOMA-B pre and post treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in insulin resistance</measure>
    <time_frame>Time Frame: 4-6 months (depending on treatment)</time_frame>
    <description>HOMA-IR pre and post treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in low-grade inflammatory markers and in adipokines</measure>
    <time_frame>Time Frame: 4-6 months (depending on treatment)</time_frame>
    <description>A panel of cytokines and adipokines</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>INF-gamma change</measure>
    <time_frame>Time Frame: 4-6 months (depending on treatment)</time_frame>
    <description>Changes in IFN-Î³ levels after incubation with saline solution, TB antigen or phytohemagglutinin A Pre, during and post treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in body composition</measure>
    <time_frame>Time Frame: 4-6 months (depending on treatment)</time_frame>
    <description>Body composition pre and post treatment measured with DEXA-scanning and/or bioimpedance</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">190</enrollment>
  <condition>Latent Tuberculosis</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>LTBI and DM</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants with LTBI and DM will be treated with Rifampicin or Isoniazid at the treating physicians discretion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LTBI without DM</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants with LTBI without DM will be treated with Rifampicin or Isoniazid at the treating physicians discretion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifampicin 300 Mg Oral Capsule</intervention_name>
    <description>Rifampicin 600 mg orally once daily for 4 months</description>
    <arm_group_label>LTBI and DM</arm_group_label>
    <arm_group_label>LTBI without DM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isoniazid 300 Mg ORAL TABLET</intervention_name>
    <description>Isoniazid 300 mg daily for 6 months</description>
    <arm_group_label>LTBI and DM</arm_group_label>
    <arm_group_label>LTBI without DM</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Inclusion criteria for the LTBIDM arm:&#xD;
&#xD;
          -  18+ years&#xD;
&#xD;
          -  Known DM type 2&#xD;
&#xD;
        Inclusion criteria for LTBI arm&#xD;
&#xD;
          -  18+ years&#xD;
&#xD;
          -  LTBI positive&#xD;
&#xD;
          -  No diagnosis with or known DM (1 and 2)&#xD;
&#xD;
        Exclusion Criteria (both arms) :&#xD;
&#xD;
          -  Previous treatment for TB or LTBI&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Type 1 DM&#xD;
&#xD;
          -  Known immunosuppression such as: HIV, steroid treatment within 14 days before&#xD;
             inclusion, daily NSAID treatment, ongoing chemotherapy, ongoing immunomodulating&#xD;
             treatment or splenectomy&#xD;
&#xD;
          -  Known contraindication to both study drugs&#xD;
&#xD;
          -  Known active liver disease&#xD;
&#xD;
          -  Known inflammatory or rheumatological diseases with immune activation such as IBD, RA,&#xD;
             Psoriasis and Wegners granulomatosis&#xD;
&#xD;
          -  Recent antibiotic treatment (&gt;2 days) or severe infection within 14 days before&#xD;
             enrollment&#xD;
&#xD;
          -  Known active cancer&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Niklas Lorentsson, MD</last_name>
    <phone>31617979</phone>
    <email>hans.johan.niklas.lorentsson.02@regionh.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pernille Ravn, ass.Prof</last_name>
    <email>pernille.ravn.02@regionh.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Herlev-Gentofte Hospital</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Niklas Lorentsson, MD</last_name>
      <phone>31617979</phone>
      <email>hans.johan.niklas.lorentsson.02@regionh.dk</email>
    </contact>
    <contact_backup>
      <last_name>Pernille Ravn, ass.Prof</last_name>
      <email>pernille.ravn.02@regionh.dk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 31, 2021</study_first_submitted>
  <study_first_submitted_qc>March 31, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2021</study_first_posted>
  <last_update_submitted>April 20, 2021</last_update_submitted>
  <last_update_submitted_qc>April 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Herlev and Gentofte Hospital</investigator_affiliation>
    <investigator_full_name>Niklas Lorentsson</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>low-grade inflammation</keyword>
  <keyword>glucose metabolism</keyword>
  <keyword>body composition</keyword>
  <keyword>cytokines</keyword>
  <keyword>adipokines</keyword>
  <keyword>biomarkers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Latent Tuberculosis</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rifampin</mesh_term>
    <mesh_term>Isoniazid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

